Tissue Regenix Group PLC Appointment of Non-Executive Director (2328M)
January 19 2016 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 2328M
Tissue Regenix Group PLC
19 January 2016
Tissue Regenix Group plc
("Tissue Regenix or "The Group")
Tissue Regenix Group strengthens Board with Non-Executive
appointment
York, 19 January 2016 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix") or ("The Company") the regenerative medical
devices company, is pleased to announce the appointment of Jonathan
Glenn as a Non- Executive Director with immediate effect.
Jonathan has been Chief Executive Officer at Consort Medical plc
since December 2007, having originally joined the company in
September 2006 as Chief Financial Officer. Prior to joining Consort
Medical, he held a number of senior financial roles across the
medical industry including Akubio Ltd 2005- 2006 and the Celltech
Group plc 1998-2005. He has a broad range of commercial experience
across the medical devices industry, particularly with regard to
clinical trial management and the US market place. During his time
with Celltech he was pivotal in the acquisitions of Chiroscience,
Medeva and OGS.
John Samuel, Chairman of Tissue Regenix Group said:
"We are very pleased to announce the appointment of Jonathan to
the board.
He has excellent experience in the medical devices market and we
look forward to working with him, we believe his appointment will
strengthen the Board as we move into our next stage of
development.
This is an exciting time for Tissue Regenix following the
successful commercialisation of our woundcare products in the US,
and the encouraging progress from the orthopaedic clinical trials
in the EU, as well as the ongoing work in our cardiac
applications"
Further Information:
Full name: Jonathan M Glenn
Age: 47
CORPORATE BOARDS
Consort Medical - Member of the Board and Chief Executive
Officer
FORMER CORPORATE BOARDS
Akubio Ltd. (03/2005 - 09/2006)
Oxford Glyosciences (04/1997 - 08/1998)
There is no further information to be disclosed in accordance
with the requirements of Schedule Two paragraph (g) of the AIM
rules.
For more information:
Tissue Regenix Group plc Tel: 01904
Caitlin Pearson - Corporate Communications 567 609
Officer
Jefferies International Ltd Tel: 020 7029
Simon Hardy / Harry Nicholas 8000
Tulchan Communications Tel: 020 7353
James Macey-White / Matt low 4200
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKMGMMVRMGVZM
(END) Dow Jones Newswires
January 19, 2016 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Oct 2023 to Oct 2024